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Dear Editor,
Coronavirus disease 19 (COVID-19) is caused by the 
severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2), which has affected more than 7 million people. 
High mortality rates were reported among elderly, and 
those requiring mechanical ventilation in the intensive 
care unit (ICU) [1, 2]. Understanding virus kinetics, 
and host serological response to SARS-CoV-2 is crucial 
to guide treatment, vaccine design and epidemiologi-
cal control [3]. Currently, the antibody response against 
SARS-CoV-2 in critically ill patients remains unknown.
We analyzed the antibody response in 28 critically 
Ill patients, with laboratory confirmed SARS-Cov-2 
infection, admitted to Sion hospital ICU (Switzerland), 
between March 8th and April 4th, 2020. Only patients 
with serum samples available at two different time points 
were included. Experimental methods are described in 
the electronic supplementary material.
The characteristics of the cohort are summarized in 
Table  S1-3. 27 (96%) patients required mechanical ven-
tilation, and 5 (19%) patients died. The median (IQR) 
intervals from symptom onset to ICU, and hospital 
admission were 9 (7–12), and 6 (4–10) days, respectively 
(Table  S1). 26 (93%) patients had available serum sam-
ple within ± 2 days of ICU admission. Of them, 15 (58%) 
already had virus-specific IgG antibodies. (Table S2, and 
Fig.  1a, b). The distribution of IgG seroconversion time 
from the date of ICU admission showed 2 peaks, the first 
one on admission, the second one about 20  days later. 
The median (IQR) time was 17 (1–22) days (Fig. 1b). The 
distribution of IgG seroconversion time, since the onset 
of symptoms showed only one peak, with the median 
(IQR) time at 10 (7–13) days (Fig.  1c). The proportion 
of patients with positive virus-specific IgG reached 96% 
over the follow-up period (Fig. 1a, and Table S2). At ICU 
admission, anti-N IgG levels correlated with the time 
from symptom onset (Fig. 1d). No association was seen 
between anti-N IgG levels and age, or any of the other 
clinical, and laboratory data assessed (Fig. S1). Interest-
ingly, two patients had no, or weak IgG seroconversion 
in the ICU. One had leukemia, the other one lymphoma. 
They died on day 4, and 38 respectively. Patients were 
then split into survivors (that were discharged from the 
ICU), and non-survivors (that died in the ICU) in order 
to assess if IgG seroconversion correlates with survival. 
IgG levels tended to be higher in patients that remained 
alive (mean difference ± SD, 10.3 ± 5.5, Fig. 1e). This sug-
gests that the antibody response correlates with virus 
neutralization, and functional protection [4]. Consist-
ently, SARS-CoV-2 cycle threshold of viral RNA ampli-
fication was low during the first week of ICU stay, then 
gradually increased (Fig.  1f ), simultaneously to the IgG 
seroconversion (Fig. 1g). Further large-scale studies doc-
umenting the antibody responses against different SARS-
CoV-2 antigens (Protein N, protein S), and viral clearance 
are needed to confirm our findings.
In conclusion, similarly to mild infections [4], most 
patients with severe COVID-19 developed SARS-Cov-2 
specific antibodies [5]. This data also suggest that the 
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severity of COVID-19 cannot be solely attributed to an 
impaired rate of seroconversion.
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